{"filings":[{"id":101294,"accession_number":"0001654954-26-002928","cik":1101026,"company_name":"Zivo Bioscience, Inc.","ticker":"ZIVO","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Zivo Bioscience to voluntarily deregister, cease SEC reporting; CFO and director resign","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CFO William Sullivan resigns effective March 30, 2026; board member Alison Cornell resigns immediately as part of cost-cutting measures.","Company expects to file Form 15 on March 30, 2026 to suspend SEC reporting obligations and delist from OTC markets.","CEO letter states anticipated revenue from AgTech distribution partner in coming months, targeting first-time positive cash flow.","Board compensation eliminated; CEO continues to invest personal capital; alignment with shareholders emphasized.","University of Georgia granted funds to study Zivo's product for Avian Influenza using company's algal immune-modulating technology."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":16860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117654,"accession_number":"0001654954-25-014296","cik":1101026,"company_name":"Zivo Bioscience, Inc.","ticker":"ZIVO","form_type":"8-K","filed_at":"2025-12-23T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CFO Keith Marchiando resigns; William Sullivan appointed Interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Keith Marchiando resigns as CFO effective Dec 31, 2025; receives $27,040/mo through Dec 31, 2026.","Marchiando retains option for 150,000 shares at $7.96, exercisable until June 30, 2027; all other options cancelled.","William A. Sullivan appointed Interim CFO effective Dec 19, 2025 as independent contractor at $285/hour.","Sullivan's contract is initially 60 days, auto-renewing monthly; no other compensation or equity.","Marchiando's separation includes confidentiality and non-disparagement obligations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":16860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134090,"accession_number":"0001654954-25-010579","cik":1101026,"company_name":"Zivo Bioscience, Inc.","ticker":"ZIVO","form_type":"8-K","filed_at":"2025-09-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"ZIVO CEO letter highlights algae antioxidant validation and animal health progress","summary_kind":"llm","event_type":"other","confidence":"medium","bullets":["Independent analysis showed ZIVO's algae has nearly double SOD activity vs. a competing algae product.","Poultry avian influenza study: treated birds showed delayed transmission, lower viral shedding, faster immune response.","Management and board personally invested in the Company, signaling conviction in undervalued stock.","Company targets $4.5B antibiotic-free feed market growing at 8.2% CAGR through 2033.","CEO acknowledges liquidity challenges but expects near-term revenue from nutraceutical commitments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":16860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134089,"accession_number":"0001654954-25-009772","cik":1101026,"company_name":"Zivo Bioscience, Inc.","ticker":"ZIVO","form_type":"8-K","filed_at":"2025-08-18T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Nola Masterson resigns from Zivo Bioscience board effective August 12, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ms. Masterson resigned immediately; no disagreement with company operations, policies, or practices.","She was chair of the Nominating and Governance committee and member of Audit and Compensation.","Board has not yet named a replacement for the open seat.","Company expressed gratitude for her service and contributions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":16860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134088,"accession_number":"0001654954-25-008035","cik":1101026,"company_name":"Zivo Bioscience, Inc.","ticker":"ZIVO","form_type":"8-K","filed_at":"2025-07-14T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Zivo Bioscience raises $250k initial tranche in $2M convertible debt offering","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $250k bridge promissory note with 10% annual interest, compounded annually; due after 2 years or upon $5M+ equity financing.","Note converts at lower of issuance price or 80% of qualified financing share price; prepayment allowed at 115% of principal.","Accompanying warrant to purchase 1,793 shares at issuance closing price, 5-year term, immediately exercisable.","Total offering up to $2M; proceeds for general operations; notes unsecured and junior to secured debt."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":16860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150838,"accession_number":"0001654954-25-006837","cik":1101026,"company_name":"Zivo Bioscience, Inc.","ticker":"ZIVO","form_type":"8-K","filed_at":"2025-06-11T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Zivo Bioscience shareholders elect directors, ratify auditor, and approve executive compensation at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected John B. Payne and Alison A. Cornell as Class III directors with 1,681,190 and 1,681,001 votes for, respectively; broker non-votes 792,911.","Ratified BDO USA, P.C. as independent auditor for fiscal year 2025 with 2,438,089 votes for, 53,549 against, 15,420 abstain.","Advisory approval of named executive officer compensation: 1,665,583 for, 48,443 against, 121 abstain; broker non-votes 792,911.","Total shares present at meeting: 2,507,058 (66.11% of outstanding common stock)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":16860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169775,"accession_number":"0001654954-25-000805","cik":1101026,"company_name":"Zivo Bioscience, Inc.","ticker":"ZIVO","form_type":"8-K","filed_at":"2025-01-27T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Zivo Bioscience issues 191,698 shares, raises ~$1.5M from accredited investor since Nov 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 75,000 shares at $20.19 each to one accredited investor, gross proceeds ~$1.5M.","Granted 38,478 restricted shares to non-employee directors under 2024 Equity Incentive Plan.","Issued 78,320 shares to investors under Exchange Program in exchange for cancellation of co-development agreements.","Total shares outstanding as of Jan 20, 2025: 3,738,033.","Shares issued in unregistered transactions exempt under Section 4(a)(2) and Regulation D."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":16860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169774,"accession_number":"0001654954-25-000453","cik":1101026,"company_name":"Zivo Bioscience, Inc.","ticker":"ZIVO","form_type":"8-K","filed_at":"2025-01-15T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Zivo Bioscience swaps revenue share obligations for 212,260 shares; director affiliates participate","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company authorized exchange of up to 212,260 shares for cancellation of Participation Agreements with accredited investors.","To date, completed exchanges with two investors for 14,200 shares of common stock.","Director Laith Yaldoo manages two entities expected to participate in the Exchange Program.","Exchange eliminates investor rights to future revenue share cash and a $5.3M buy-out option.","Investors retain Warrants issued under the original Participation Agreements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":16860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169773,"accession_number":"0001654954-25-000173","cik":1101026,"company_name":"Zivo Bioscience, Inc.","ticker":"ZIVO","form_type":"8-K","filed_at":"2025-01-07T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"ZIVO BIOSCIENCE moves principal executive office to Troy, Michigan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Effective January 6, 2025, principal executive office changed to 2125 Butterfield Drive, Suite 100, Troy, MI 48084.","Previous address was 21 East Long Lake Road, Suite 100, Bloomfield Hills, MI 48304.","Company telephone number (+1 248 452-9866) remains unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":16860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186824,"accession_number":"0001654954-24-014503","cik":1101026,"company_name":"Zivo Bioscience, Inc.","ticker":"ZIVO","form_type":"8-K","filed_at":"2024-11-15T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Zivo restructures $277k debt into unsecured notes payable over 24 months at 1%","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Debt Settlement Agreements with three creditors executed on Nov 12, 2024.","Total principal $277,254 via notes to Howard Shapiro ($185.5k), Merger Masters ($40.3k), Financial Trading ($51.4k).","Notes bear 1% annual interest, payable in 24 equal monthly installments starting Nov 30, 2024.","Prepayment permitted without penalty; customary events of default apply.","Restructuring converts existing obligations into unsecured promissory notes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":16860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186823,"accession_number":"0001654954-24-013107","cik":1101026,"company_name":"Zivo Bioscience, Inc.","ticker":"ZIVO","form_type":"8-K","filed_at":"2024-10-18T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Zivo Bioscience sells 169,022 unregistered shares at avg $10.44 to accredited investors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 169,022 shares between Aug 22 and Oct 17, 2024, at $8.34 to $16.31 per share (avg $10.44).","Of total, 52,802 shares sold to related parties at avg $9.68 per share.","No solicitation or underwriting discounts; exempt under Section 4(a)(2) and Regulation D.","As of Oct 17, 2024, outstanding shares total 3,535,134 (dilution ~4.8% from offering).","Proceeds used for general corporate purposes (not stated, typical for such offerings)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":16860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203361,"accession_number":"0001654954-24-009069","cik":1101026,"company_name":"Zivo Bioscience, Inc.","ticker":"ZIVO","form_type":"8-K","filed_at":"2024-07-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"ZIVO Bioscience appoints Laith Yaldoo to board, expands to 5 members","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board increased from 4 to 5 members; Laith Yaldoo appointed effective July 11, 2024.","Yaldoo is managing member of HEP Investments LLC; background in biotech, healthcare, and card processing.","He will stand for election as a Class I director at the 2026 annual meeting.","No family relationships or related party transactions with current officers/directors.","Yaldoo will participate in the Company’s standard outside director compensation program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":16860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219742,"accession_number":"0001654954-24-007730","cik":1101026,"company_name":"Zivo Bioscience, Inc.","ticker":"ZIVO","form_type":"8-K","filed_at":"2024-06-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Zivo shareholders elect Masterson as director, ratify BDO, approve say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Nola E. Masterson elected Class II director (1,155,796 for, 80,935 withheld; 625,589 broker non-votes).","BDO USA, LLP ratified as auditor for FY 2024 (1,767,252 for, 94,680 against, 388 abstain).","Advisory say-on-pay approved (1,191,591 for, 44,773 against, 367 abstain; 625,589 broker non-votes).","Total shares voted: 1,862,320 (66.4% of outstanding common stock)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":16860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219740,"accession_number":"0001654954-24-007479","cik":1101026,"company_name":"Zivo Bioscience, Inc.","ticker":"ZIVO","form_type":"8-K/A","filed_at":"2024-06-07T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Zivo Bioscience amends 8-K to correct date typo in director stock award from 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Corrects date in Item 1.01 from erroneous date to December 29, 2023.","Board approved 261,619 shares to three non-employee directors for unpaid 2023 fees of $172,670.","Shares issued at $1.20 per share (Dec 29, 2023 close), grossed up for taxes at 45%.","Directors Cornell (95k), Masterson (85k), Maggiore (82k) accepted grants on June 5, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":16860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219741,"accession_number":"0001654954-24-007455","cik":1101026,"company_name":"Zivo Bioscience, Inc.","ticker":"ZIVO","form_type":"8-K","filed_at":"2024-06-06T23:59:59+00:00","items":["1.01","5.02","3.02","9.01"],"status":"ready","headline":"Zivo Bioscience adopts new Director Equity Plan, boosts share reserves, grants equity to directors and officers","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Adopted 2024 Director Equity Plan (875k shares, auto-increase 5%/yr). Director cash fee raised from $40k to $50k, eligible for restricted stock/RSUs.","Amended 2021 Plan reserve from 166,666 to 1,000,000 shares; terminated 2019 Plan.","Granted 127,364 restricted shares to directors replacing cancelled options; additional 261,619 shares for unpaid 2023 fees.","Issued 1,031,425 stock options to officers: CEO John Payne (217,431), CFO Keith Marchiando (444,498) replacing prior options and cash bonus.","Total unregistered securities issued: 426,671 common shares and options for 1,031,425 shares; outstanding shares at 3,278,807."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":16860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239525,"accession_number":"0001654954-24-001856","cik":1101026,"company_name":"Zivo Bioscience, Inc.","ticker":"ZIVO","form_type":"8-K","filed_at":"2024-02-15T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Nasdaq formally delists Zivo Bioscience common stock and warrants","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq announced formal delisting on Feb 13, 2024; will file Form 25 with SEC.","Trading suspended Nov 27, 2023 due to noncompliance with Listing Rule 5550(b)(1) (minimum equity).","Common stock now trades on OTCQB under ZIVO; warrants trade on Pink Sheets under ZIVOW."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":16860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239524,"accession_number":"0001654954-24-000694","cik":1101026,"company_name":"Zivo Bioscience, Inc.","ticker":"ZIVO","form_type":"8-K","filed_at":"2024-01-17T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Zivo Bioscience sells 174,145 unregistered shares to accredited investors at avg $3.05/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 174,145 common shares at $2.82–$4.02 each (avg $3.05), relying on Section 4(2) and Regulation D.","No underwriter discounts or commissions; transaction exempt from registration under Securities Act.","As of Jan 16, 2024, outstanding common shares totaled 2,748,167."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":16860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239523,"accession_number":"0001654954-24-000274","cik":1101026,"company_name":"Zivo Bioscience, Inc.","ticker":"ZIVO","form_type":"8-K","filed_at":"2024-01-05T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Zivo Bioscience sells 288,359 unregistered shares at avg $1.27 to accredited investors","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Sold 288,359 shares of common stock between Dec 29, 2023 and Jan 3, 2024.","Prices ranged $1.20–$1.30 per share; average price $1.27.","Offering was made to accredited investors under Rule 506(b) exemption.","No underwriting discounts or commissions were paid.","Shares not registered under Securities Act; proceeds used for working capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":16860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239522,"accession_number":"0001654954-24-000154","cik":1101026,"company_name":"Zivo Bioscience, Inc.","ticker":"ZIVO","form_type":"8-K","filed_at":"2024-01-03T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Zivo raises ~$309k via private placement of 266,324 shares at avg $1.16","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 266,324 shares at prices between $1.00 and $1.35 per share (avg $1.16) to accredited investors.","Gross proceeds approximately $309,000; no underwriting discounts or commissions paid.","Offering relied on Section 4(2) and Regulation D exemption; shares not registered under Securities Act.","Sales occurred between December 12 and December 27, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":16860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257050,"accession_number":"0001654954-23-015370","cik":1101026,"company_name":"Zivo Bioscience, Inc.","ticker":"ZIVO","form_type":"8-K","filed_at":"2023-12-11T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Zivo closes $200,000 private placement of 200,000 shares at $1.00 each","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 200,000 common shares at $1.00 per share to an accredited investor on Dec 5, 2023.","Total gross proceeds of $200,000; no underwriting discounts or commissions paid.","Shares issued in reliance on Section 4(2) and Regulation D exemption; no public solicitation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":16860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257049,"accession_number":"0001654954-23-014775","cik":1101026,"company_name":"Zivo Bioscience, Inc.","ticker":"ZIVO","form_type":"8-K","filed_at":"2023-11-27T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"ZIVO Bioscience receives Nasdaq delisting notice; shares to trade on OTC Pink Sheets","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified ZIVO on Nov 22, 2023 of delisting for noncompliance with Listing Rule 5550(b)(1).","Trading suspended on Nasdaq effective Nov 27, 2023; company expects to trade on OTC Pink Sheets same day under symbol ZIVO.","Company has applied for OTCQB quotation; pending approval, shares will trade on OTC Pink Sheets.","Transition to OTC Markets will not affect business or operations; company will continue SEC reporting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":16860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257048,"accession_number":"0001654954-23-014712","cik":1101026,"company_name":"Zivo Bioscience, Inc.","ticker":"ZIVO","form_type":"8-K","filed_at":"2023-11-22T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Zivo Bioscience issues $150,000 10% promissory note to HEP Investments","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Principal amount $150,000; interest at 10% per annum; matures May 16, 2024.","Company has option to extend maturity date by an additional six months.","No prepayment penalty; note issued in private placement under Section 4(a)(2).","Subscriber HEP Investments, LLC is a significant shareholder of the Company.","Proceeds for general corporate purposes as determined by management."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":16860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257047,"accession_number":"0001654954-23-013408","cik":1101026,"company_name":"Zivo Bioscience, Inc.","ticker":"ZIVO","form_type":"8-K","filed_at":"2023-10-26T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"Zivo Bioscience effects 1-for-6 reverse stock split to regain Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["1-for-6 reverse split effective 5:00 p.m. ET Oct 26, 2023; trading split-adjusted Oct 27.","Authorized shares reduced from 150M to 25M; par value $0.001 unchanged.","No fractional shares issued; cash in lieu based on Oct 26 closing price.","Proportional adjustments to warrants, stock options, and equity plan shares.","Reverse split intended to meet Nasdaq continued listing requirements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":16860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274380,"accession_number":"0001654954-23-010378","cik":1101026,"company_name":"Zivo Bioscience, Inc.","ticker":"ZIVO","form_type":"8-K","filed_at":"2023-08-09T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Zivo Bioscience granted Nasdaq extension to Nov 20, 2023 to regain equity compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received deficiency notice on May 23, 2023 for stockholders' equity below $2.5M (Listing Rule 5550(b)).","Nasdaq Hearings Panel held on July 13, 2023; extension granted until November 20, 2023.","Extension conditioned on filing Form S-1 with SEC by October 5, 2023.","Company intends to regain compliance but delisting risk remains; potential adverse effect on capital access."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":16860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274379,"accession_number":"0001654954-23-008880","cik":1101026,"company_name":"Zivo Bioscience, Inc.","ticker":"ZIVO","form_type":"8-K","filed_at":"2023-07-06T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"ZIVO Bioscience raises ~$4.0M in registered direct offering and concurrent private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 1,498,130 shares/pre-funded warrants at $2.67/unit to institutional investor for ~$4.0M gross proceeds.","Concurrent private placement of Series A (2-yr) and Series B (5-yr) warrants exercisable for 1,498,130 shares each at $2.80.","Offering expected to close July 5, 2023; Maxim Group LLC is sole placement agent.","Shares offered under effective S-3 registration; warrants unregistered under Section 4(a)(2)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":16860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":291634,"accession_number":"0001654954-23-008091","cik":1101026,"company_name":"Zivo Bioscience, Inc.","ticker":"ZIVO","form_type":"8-K","filed_at":"2023-06-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Zivo Bioscience stockholders elect Maggiore, ratify BDO, approve exec compensation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Christopher D. Maggiore elected to board with 3,050,053 votes for, 393,297 withheld; 2,704,419 broker non-votes.","BDO USA, LLP ratified as auditor for FY2023: 5,982,232 for, 164,958 against, 579 abstain.","Advisory vote on executive compensation approved: 3,252,348 for, 186,946 against, 4,056 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":16860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":291633,"accession_number":"0001654954-23-007294","cik":1101026,"company_name":"Zivo Bioscience, Inc.","ticker":"ZIVO","form_type":"8-K","filed_at":"2023-05-26T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Zivo Bioscience receives Nasdaq delisting notice for $2.5M equity non-compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Zivo on May 23, 2023 that it fails to meet $2.5M stockholders' equity requirement (Listing Rule 5550(b)).","Company plans to request a hearing before Nasdaq Hearings Panel to stay delisting pending compliance plan.","Previously granted extension to evidence compliance expired May 22, 2023; company was unable to cure.","No assurance that Panel will grant continued listing or that company can regain compliance within any extension."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":16860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":291632,"accession_number":"0001654954-23-004459","cik":1101026,"company_name":"Zivo Bioscience, Inc.","ticker":"ZIVO","form_type":"8-K","filed_at":"2023-04-05T23:59:59+00:00","items":["1.01","2.03","3.02","8.01","9.01"],"status":"ready","headline":"Zivo Bioscience receives $1M bridge loan from CEO John Payne with 10% interest and warrants","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["CEO John Payne provides $1M unsecured six-month loan at 10% simple interest, extendable six months.","Warrants to purchase 390,000 shares at $2.91 per share, exercisable for three years.","Proceeds for working capital, coccidiosis validation study in broiler chickens, and strategic alternatives.","Company expects to complete titration study in May 2023, then 42-day study in over 2,000 chickens by mid-2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":16860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312407,"accession_number":"0001654954-23-001582","cik":1101026,"company_name":"Zivo Bioscience, Inc.","ticker":"ZIVO","form_type":"8-K","filed_at":"2023-02-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ZIVO BIOSCIENCE announces study results; full details not in filing excerpt","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Press release dated February 10, 2023 issued regarding results of a recent study.","Complete text of Exhibit 99.1 is not included in the provided filing excerpt.","No specific study outcomes, numbers, or conclusions are extractable."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":16860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":330951,"accession_number":"0001654954-22-015844","cik":1101026,"company_name":"Zivo Bioscience, Inc.","ticker":"ZIVO","form_type":"8-K","filed_at":"2022-11-29T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Zivo Bioscience receives Nasdaq delisting notice for insufficient equity","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Zivo on Nov 22, 2022 of non-compliance with minimum $2.5M stockholders' equity requirement.","Equity fell below threshold as of Sept 30, 2022; alternative compliance standards also not met.","Company has 45 days (until Jan 6, 2023) to submit a plan to regain compliance; possible 180-day extension.","No immediate impact on trading; common stock (ZIVO) and warrants (ZIVOW) continue trading on Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":16860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":348502,"accession_number":"0001654954-22-011676","cik":1101026,"company_name":"Zivo Bioscience, Inc.","ticker":"ZIVO","form_type":"8-K","filed_at":"2022-08-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Zivo Bioscience receives USDA CVB jurisdiction for coccidiosis biologic; new study in Sept 2022","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["USDA CVB affirms jurisdiction over novel immune-modulating biologic for coccidiosis in broilers, removing regulatory ambiguity.","Company continues licensing discussions with a major animal health company for product candidate.","Strategic partner to begin 42-day in vivo study in September 2022; results expected Q1 2023.","No financial results or guidance were provided in this corporate update."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":16860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":348501,"accession_number":"0001654954-22-010528","cik":1101026,"company_name":"Zivo Bioscience, Inc.","ticker":"ZIVO","form_type":"8-K","filed_at":"2022-08-03T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Zivo Bioscience shareholders elect four directors, ratify BDO as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Maggiore (Class I), Masterson (Class II), Payne and Cornell (Class III) to board with 3.4M+ votes for each.","Ratified BDO USA as auditor for FY2022 with 6,067,848 for, 139,397 against.","Advisory vote on executive compensation passed with 3,805,069 for, 125,306 against.","Turnout: 6,208,928 shares represented (approx 66% of outstanding)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":16860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":348500,"accession_number":"0001654954-22-009385","cik":1101026,"company_name":"Zivo Bioscience, Inc.","ticker":"ZIVO","form_type":"8-K","filed_at":"2022-07-07T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Zivo Bioscience adopts staggered board, eliminates shareholder written consent","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved Second Amended and Restated Bylaws effective June 30, 2022.","Creates three-class staggered board; only one class elected per annual meeting after initial election.","Eliminates stockholder ability to take action by written consent.","Only the Board may appoint directors to fill vacancies or change the number of directors.","Adds modernizing provisions for electronic meetings and access to corporate records."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":16860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":365206,"accession_number":"0001654954-22-008906","cik":1101026,"company_name":"Zivo Bioscience, Inc.","ticker":"ZIVO","form_type":"8-K","filed_at":"2022-06-28T23:59:59+00:00","items":["5.08"],"status":"ready","headline":"Zivo Bioscience sets 2022 Annual Meeting for July 28; new deadlines for proposals and nominations","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Annual Meeting scheduled for July 28, 2022; record date fixed as June 28, 2022.","Deadline for stockholder proposals to be included in proxy materials is July 1, 2022.","Deadline for director nominations by stockholders is July 14, 2022.","Meeting date changed by more than 30 days from 2021 Annual Meeting, triggering new submission deadlines."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":16860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":365205,"accession_number":"0001654954-22-007313","cik":1101026,"company_name":"Zivo Bioscience, Inc.","ticker":"ZIVO","form_type":"8-K","filed_at":"2022-05-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Zivo Bioscience updates: USDA white paper, new poultry study, licensing talks with major animal health firm","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Submitted white paper to USDA for poultry coccidiosis product; expects jurisdiction confirmation within 8 weeks.","Began 21st in vivo study with AH Pharma to optimize product forms and reduce production costs.","Ongoing licensing discussions with a major animal health company; decision expected by end of Q2 2022.","Previous 20 studies validated efficacy and mechanism of action for the lead product candidate."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":16860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":365204,"accession_number":"0001654954-22-005373","cik":1101026,"company_name":"Zivo Bioscience, Inc.","ticker":"ZIVO","form_type":"8-K","filed_at":"2022-04-25T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"ZIVO regains Nasdaq compliance after late 10-K filing cured","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received noncompliance notice on April 19, 2022 for failing to timely file 2021 10-K.","Filed the Form 10-K on April 22, 2022 to regain compliance.","Nasdaq confirmed compliance regained on April 25, 2022 and closed the matter.","No immediate effect on listing or trading of common stock during the notice period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":16860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":365203,"accession_number":"0001654954-22-005068","cik":1101026,"company_name":"Zivo Bioscience, Inc.","ticker":"ZIVO","form_type":"8-K","filed_at":"2022-04-15T23:59:59+00:00","items":["4.02"],"status":"ready","headline":"Zivo Bioscience restates Q3 2021 financials; delays 2021 10-K filing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Error in accounting for License Co-Development Participation Agreements; restates net loss for Q3 2021 from -$1.93M to -$1.58M.","Deferred R&D obligation restated to $1.68M; total current liabilities reduced by $350K.","Concluded internal controls over financial reporting were ineffective; material weakness disclosed.","Company expects to file amended 10-Q and 10-K after restatement; filed NT 10-K on March 31, 2022.","Restatement reduces accumulated deficit by $350K to ~$104.7M as of Sep 30, 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":16860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":384792,"accession_number":"0001654954-22-002336","cik":1101026,"company_name":"Zivo Bioscience, Inc.","ticker":"ZIVO","form_type":"8-K/A","filed_at":"2022-03-01T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Zivo reaffirms former CEO Andrew Dahl was terminated for cause, disputes his email claims","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Company states Board terminated Andrew Dahl for cause; he was offered chance to resign before termination.","Dahl's email (Exhibit 17) challenged company's account; Company maintains its initial filing was accurate.","Company confirms it filed original 8-K and this amendment within SEC-prescribed timelines."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":16860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":384795,"accession_number":"0001654954-22-002090","cik":1101026,"company_name":"Zivo Bioscience, Inc.","ticker":"ZIVO","form_type":"8-K","filed_at":"2022-02-25T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Zivo Bioscience terminates CEO Andrew Dahl for cause; Dahl resigns from board","summary_kind":"llm","event_type":"leadership","confidence":"medium","bullets":["CEO Andrew A. Dahl terminated for cause on Jan 4, 2022 after declining to resign; no separation agreement reached.","On Feb 18, 2022, Dahl resigned from the board of directors; board size reduced to four members.","Principal executive office moved to 21 E. Long Lake Road, Suite 100, Bloomfield Hills, MI effective Feb 21, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":16860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":384794,"accession_number":"0001654954-22-001759","cik":1101026,"company_name":"Zivo Bioscience, Inc.","ticker":"ZIVO","form_type":"8-K","filed_at":"2022-02-16T23:59:59+00:00","items":["4.01","5.02","9.01"],"status":"ready","headline":"Zivo Bioscience appoints BDO as auditor and finalizes CEO John Payne's employment contract","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Appointed BDO USA, LLP as independent auditor effective February 10, 2022, replacing resigned auditor Wolinetz, Lafazan & Company.","CEO John Payne's contract provides $400k annual salary, bonus up to 125% of salary, and annual equity awards valued at $400k.","ZIVO 2021 Plan reserves 1,000,000 shares with automatic annual increase of 5% of outstanding shares through 2031."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":16860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":384793,"accession_number":"0001654954-22-000342","cik":1101026,"company_name":"Zivo Bioscience, Inc.","ticker":"ZIVO","form_type":"8-K","filed_at":"2022-01-11T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"ZIVO Bioscience terminates CEO Andrew Dahl; Chairman John Payne named President and CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Andrew A. Dahl terminated as President and CEO on January 4, 2022.","John B. Payne, previously Chairman, appointed President and CEO effective January 7, 2022.","Payne founded Compassion-First Pet Hospitals; served as President and CEO until 2020.","Payne removed from Compensation and Audit Committees; Christopher Maggiore appointed.","Company highlights 2021 progress including Nasdaq uplisting; expects seamless transition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":16860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":402684,"accession_number":"0001654954-21-013009","cik":1101026,"company_name":"Zivo Bioscience, Inc.","ticker":"ZIVO","form_type":"8-K/A","filed_at":"2021-12-10T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Zivo Bioscience auditor Wolinetz, Lafazan resigns on Nov 30, 2021","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Wolinetz, Lafazan & Company resigned as independent auditor effective Nov 30, 2021, citing personal reasons.","No disagreements or reportable events occurred during the two most recent fiscal years or subsequent interim periods.","Audit reports for FY2020 and FY2019 included a going-concern explanatory paragraph but were unqualified.","Company's board is currently seeking a replacement independent registered public accounting firm."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":16860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":402687,"accession_number":"0001654954-21-012958","cik":1101026,"company_name":"Zivo Bioscience, Inc.","ticker":"ZIVO","form_type":"8-K","filed_at":"2021-12-09T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Zivo Bioscience's auditor Wolinetz, Lafazan resigns effective Nov 30, 2021; no disagreements","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Independent auditor Wolinetz, Lafazan & Company resigned on Nov 30, 2021 for personal reasons unrelated to Zivo.","Reports for fiscal years ended Dec 31, 2020 and 2019 were unqualified; no adverse opinions or modifications.","No disagreements on accounting principles or reportable events during the two most recent fiscal years and interim periods.","Board is in process of identifying and engaging a new independent registered public accounting firm."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":16860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":402686,"accession_number":"0001654954-21-011071","cik":1101026,"company_name":"Zivo Bioscience, Inc.","ticker":"ZIVO","form_type":"8-K","filed_at":"2021-10-14T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Zivo Bioscience reports shareholder votes: directors elected, equity plan approved, auditor ratified","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All five director nominees elected with >95% votes for (excluding broker non-votes).","Ratification of Wolinetz, Lafazan & Company as auditor approved with 98% of votes cast.","2021 Equity Incentive Plan approved with ~90% of votes for (excluding broker non-votes).","Advisory say-on-pay approved with ~94% of votes for (excluding broker non-votes).","60.6% of outstanding shares represented at the annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":16860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":402685,"accession_number":"0001654954-21-010969","cik":1101026,"company_name":"Zivo Bioscience, Inc.","ticker":"ZIVO","form_type":"8-K","filed_at":"2021-10-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Zivo Bioscience files 8-K on annual meeting presentation; no specifics disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Presentation delivered at October 12, 2021 Annual Meeting of Shareholders.","Slides furnished as Exhibit 99.1, but content not summarized in the filing.","No material updates on financials, operations, or guidance provided in the 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":16860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":421595,"accession_number":"0001654954-21-010264","cik":1101026,"company_name":"Zivo Bioscience, Inc.","ticker":"ZIVO","form_type":"8-K","filed_at":"2021-09-21T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Zivo Bioscience director Rondeau resigns; board reduced to 5; committee appointments","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Rondeau resigned effective Sep 17, 2021; no disagreement with company operations.","Board size reduced from six to five directors effective Sep 17.","Alison Cornell appointed to Compensation Committee; John Payne to Nominating and Corporate Governance Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":16860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":421594,"accession_number":"0001654954-21-010151","cik":1101026,"company_name":"Zivo Bioscience, Inc.","ticker":"ZIVO","form_type":"8-K/A","filed_at":"2021-09-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Zivo Bioscience board adopts annual say-on-pay vote frequency","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shareholders cast most votes for annual say-on-pay frequency at Nov 2020 meeting.","Board determined to hold future say-on-pay votes on an annual basis.","Annual frequency will continue until next required vote on frequency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":16860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}